...
机译:通过抑制多发性骨髓瘤中的NF-κB信号传导途径抑制Nortezomib酶USP7克服脱硫酶USP7
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
Blood Disease InstituteXuzhou Medical UniversityXuzhou Jiangsu China;
bortezomib‐resistant; IκBα; multiple myeloma; USP7;
机译:通过抑制多发性骨髓瘤中的NF-κB信号传导途径抑制Nortezomib酶USP7克服脱硫酶USP7
机译:血红素氧合酶-1抑制硼替佐米对多发性骨髓瘤细胞中的4月NF-κB-CCL3信号通路的抑制作用:多种骨髓瘤中的硼佐米耐药强制
机译:通过抑制MTOR / NF-κB信号通路,PLD1封锁增强了硼瘤细胞中Bortezomib的抗肿瘤作用
机译:Bortezomib抗性多发性骨髓瘤的初步大规模定量蛋白质组学分析
机译:范可尼贫血(FA)/ BRCA DNA损伤修复途径受NF-κB调节并介导多发性骨髓瘤的耐药性。
机译:阻断泛素化酶Rpn11触发多发性骨髓瘤细胞凋亡并克服硼替佐米耐药
机译:依鲁替尼抑制BTK驱动的NF-κBp65活性以克服多发性骨髓瘤中对硼替佐米的耐药性